Document Detail

Effect of intravitreal bevacizumab (Avastin(®)) therapy in malignant hypertensive retinopathy: a report of two cases.
MedLine Citation:
PMID:  22149905     Owner:  NLM     Status:  MEDLINE    
PURPOSE: Malignant hypertensive retinopathy is a rare, but serious, complication of uncontrolled systemic hypertension for which no treatment has been established yet. We report 2 patients with malignant hypertensive retinopathy who recovered promptly following intravitreal bevacizumab injection.
METHODS: Intravitreal bevacizumab (1.25 mg/0.05 mL) was injected in 4 eyes of 2 patients having malignant hypertensive retinopathy with optic disc edema, macular edema, and retinal exudates. A complete ophthalmic examination, including the best-corrected visual acuity (BCVA), central macular thickness (CMT) on optical coherence tomography (OCT), and fluorescein angiography (FAG), was performed before and after the treatments.
RESULTS: Two eyes in 1 patient received two intravitreal injections of bevacizumab, whereas 2 eyes in the other patient received a single treatment. All 4 eyes had improvement of macular edema on OCT at 1 month and decreased fluorescein leakage on FAG 3 months after the treatment, which led to improvements in the BCVA in 3 eyes. In 1 eye with foveal atrophy, no change in the BCVA occurred despite the improved macular edema on OCT.
CONCLUSIONS: The results suggest that intravitreal bevacizumab injections might be a useful adjunctive treatment of malignant hypertensive retinopathy in some selected cases. However, further studies are mandatory to determine the safety and the efficacy of such injections in this disease.
Eui Yon Kim; Ho Min Lew; Ji Hun Song
Related Documents :
16562055 - Physiological effects of a constitutive tryptophanase in bacillus alvei.
10537045 - Tau is modified by tissue transglutaminase in situ: possible functional and metabolic e...
23177365 - Anterior segment optical coherence tomography-guided big-bubble technique.
25390785 - Primary central nervous system lymphoma with intraocular recurrence after optic nerve d...
9786565 - Effect of fiberoptic diameter in diode laser transscleral cyclophotocoagulation in huma...
12388035 - Trypan blue as an adjunct for safe phacoemulsification in eyes with white cataract.
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2011-12-09
Journal Detail:
Title:  Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics     Volume:  28     ISSN:  1557-7732     ISO Abbreviation:  J Ocul Pharmacol Ther     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-06-08     Completed Date:  2013-01-16     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  9511091     Medline TA:  J Ocul Pharmacol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  318-22     Citation Subset:  IM    
Department of Ophthalmology, Ajou University School of Medicine, Suwon, Republic of Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiogenesis Inhibitors / administration & dosage*
Antibodies, Monoclonal, Humanized / administration & dosage*
Hypertension, Malignant / drug therapy*
Hypertensive Retinopathy / drug therapy*
Intravitreal Injections / methods
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V/bevacizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Silymarin, a molecule of interest for topical photoprotection.
Next Document:  Role of magnetic resonance cholangiopancreatography for choledocholithiasis: Analysis of patients wi...